CRISPR Therapeutics had its first FDA-approved product in December 2023, a treatment for sickle cell disease called Casgevy. It’s also developing treatments for cancer and cardiovascular disease using ...

Recent commentary has highlighted CRISPR Therapeutics’ expanding gene-editing pipeline, including cardiovascular candidates like CTX310 and CTX320 and programs in type 1 diabetes, alongside fresh Buy ...

CRISPR technology, targeting genetic diseases and cancer, may bring major biotech stock growth. CRISPR Therapeutics and Intellia show progress with clinical trials and big pharma partnerships.

For the millions of people living with genetic diseases like muscular dystrophy and inherited liver disorders, one of the ...

There are plenty of reasons, though, to be bullish on the stock, not the least of which is its improved cash position. The ...

Last month, CRSP reported initial top-line results from an early-stage study on CTX310, its investigational in vivo CRISPR-based gene therapy, designed to target ANGPTL3 for the treatment of ...

A research team led by geneticist Jeannie Lee at Harvard Medical School, cell biologist Jeanne Lawrence at UMass Chan Medical ...

Add Yahoo as a preferred source to see more of our stories on Google. Stanford researchers have developed CRISPR-GPT, an AI-powered copilot that guides gene-editing experiments. (CREDIT: Shutterstock) ...

Banas is associate director of research at the Gene Editing Institute at ChristianaCare, where Kmiec is founder and executive director. The medical promise of CRISPR gene editing can be seen most ...

CRISPR functions as a programmable genetic memory system derived from bacterial immune defenses against viral infections. Guide RNA allows for rapid multiplexed targeting compared to older ...

A newly discovered RNA-based mechanism helps CRISPR systems maintain efficiency by preventing interference, offering insights ...